Altimmune, Inc. (ALT) P/E Ratio History
Historical price-to-earnings valuation from 2017 to 2017
Loading P/E history...
ALT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Altimmune, Inc. (ALT) trades at a price-to-earnings ratio of -3.0x, with a stock price of $3.04 and trailing twelve-month earnings per share of $-0.88.
The current P/E is 1145% below its 5-year average of 0.3x. Over the past five years, ALT's P/E has ranged from a low of 0.3x to a high of 0.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ALT trades at a 114% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ALT trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ALT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ALT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 25.5 | 1.11 | -25% | |
| $2B | 6.9Lowest | 0.67Best | +817%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ALT Historical P/E Data (2017–2017)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2017 Q3 | Sat Sep 30 2017 00:00:00 GM | $69.60 | $264.64 | 0.3x | -10% |
| FY2017 Q2 | Fri Jun 30 2017 00:00:00 GM | $96.00 | $301.12 | 0.3x | +10% |
Average P/E for displayed period: 0.3x
See ALT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALT — Frequently Asked Questions
Quick answers to the most common questions about buying ALT stock.
Is ALT stock overvalued or undervalued?
ALT trades at -3.0x P/E, below its 5-year average of 0.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ALT's valuation compare to peers?
Altimmune, Inc. P/E of -3.0x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ALT's PEG ratio?
ALT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2017-2017.